Nor Isamuddin N H, Hanuar N F, AbuBakar S, Tan K K, Chin K L, Zainal N
Tropical Infectious Diseases Research and Education Centre (TIDREC), University of Malaya, 50603 Kuala Lumpur, Malaysia.
Institute for Advanced Studies, Advanced Studies Complex, Universiti Malaya, 50603 Kuala Lumpur, Malaysia.
Trop Biomed. 2025 Jun 1;42(2):184-193. doi: 10.47665/tb.42.2.011.
Chikungunya virus (CHIKV) and Japanese encephalitis virus (JEV) are mosquito-borne arboviruses that pose significant public health risks, especially in tropical regions like Malaysia. CHIKV is linked to joint and muscle pain, while JEV can cause severe neurological illnesses and encephalitis if untreated. With no specific treatments available, research into potential antivirals is crucial. This study investigates the inhibitory potential of resveratrol (RES) against CHIKV and JEV in vitro. Cytotoxicity of RES was assessed on human adenocarcinoma alveolar basal epithelial cells (A549) using the MTS assay, followed by dose-dependent analyses to determine optimal inhibitory concentrations. Antiviral effects were explored through pre-infection, post-infection, virucidal, and anti-adsorption assays, with virus titres measured via plaque and foci-forming assays for CHIKV and JEV, respectively. Results revealed that RES's pre- and post-infection treatments significantly reduced titres of both viruses in a dose-dependent manner. Notably, CHIKV titres were reduced by over 65% (p < 0.01) when treated with 100 µM RES, whether administered pre-infection or post-infection. For JEV, a reduction of over 93% (p < 0.05) was observed only with post-infection treatment, while pre-infection treatment alone did not yield a significant reduction. In addition, both pre-incubation and anti-adsorption assays for CHIKV and JEV showed no significant results. These findings suggest that RES likely inhibits viral replication by modulating host cellular mechanisms rather than directly targeting the viruses. In summary, this study demonstrates that RES exhibits antiviral properties against CHIKV and JEV replication, underscoring its potential as an effective antiviral agent. However, further in vivo studies are needed to fully evaluate its therapeutic potential and efficacy.
基孔肯雅病毒（CHIKV）和日本脑炎病毒（JEV）是蚊媒虫媒病毒，会带来重大的公共卫生风险，尤其是在马来西亚等热带地区。CHIKV与关节和肌肉疼痛有关，而JEV如果不治疗会导致严重的神经系统疾病和脑炎。由于没有可用的特效治疗方法，对潜在抗病毒药物的研究至关重要。本研究调查了白藜芦醇（RES）在体外对CHIKV和JEV的抑制潜力。使用MTS法评估RES对人肺腺癌肺泡基底上皮细胞（A549）的细胞毒性，随后进行剂量依赖性分析以确定最佳抑制浓度。通过感染前、感染后、杀病毒和抗吸附试验探索抗病毒效果，分别通过噬斑试验和蚀斑形成试验测定CHIKV和JEV的病毒滴度。结果显示，RES感染前和感染后的治疗均以剂量依赖性方式显著降低了两种病毒的滴度。值得注意的是，用100μM RES治疗时，无论在感染前还是感染后给药，CHIKV滴度均降低了65%以上（p<0.01）。对于JEV，仅在感染后治疗时观察到滴度降低超过93%（p<0.05），而单独的感染前治疗未产生显著降低。此外，CHIKV和JEV的预孵育试验和抗吸附试验均未显示出显著结果。这些发现表明，RES可能通过调节宿主细胞机制而非直接靶向病毒来抑制病毒复制。总之，本研究表明RES对CHIKV和JEV复制具有抗病毒特性，突出了其作为有效抗病毒剂的潜力。然而，需要进一步的体内研究来全面评估其治疗潜力和疗效。
